November 14, 2023
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer(Securities Code: 4582)

Revision to Earnings Forecast and Reversal of deferred tax assets for FY 2023

TOKYO, Japan, November 14, 2023 – SymBio Pharmaceuticals Limited (Headquarters: Tokyo,“SymBio” or the “Company”) today announced that the Company’s Board of Directors today approved
the following revision to the earnings forecast for fiscal year ending December 31, 2023. The earnings
forecast was previously announced on August 3, 2023. The revision reflects the Company’s current
performance trends and outlook.

1. Revision to Earnings Forecast
1) Revision to Earnings Forecast for FY 2023 (January 1, 2023 to December 31, 2023)
ProfitEarnings

OperatingOrdinary

ProfitProfitYen millions

Yen millions

Yen millions

Yen millions

Yen

Previous Forecast (A)6,477

Revised Forecast (B)

5,603

(331)

(680)

(549)

(1,291)

(874)

(921)

(9.34)

Difference (B-A)

(330)

(370)

(32.53)

(349)

(219)

－Percentage Change (%)(13.5)－－－－

10,008

1,963

1,999

1,179

30.20

Net Sales

attributable toowners of parentper share[Reference] Prior Year
Results (FY 2022)

2) Reasons for changes
Although the impacts of generic bendamustine products were generally in line with our expectations,the overall bendamustine market has contracted due to a continuing decline in prescriptions andtreatment delays due to seasonal influenza and COVID-19. As a result, the Company revised its net
sales forecast downward to 5,603 million yen, which is a reduction of 874 million yen compared to thepreviously announced forecast. The impacts of seasonal influenza and COVID-19 are anticipated tocontinue contracted through the current fiscal year.

1While continuing to prioritize R&D investment in ongoing global development of brincidofovir (“BCV”),
the Company has reduced selling, general, and administrative expenses to mitigate adverse effects ofthe decrease in sales. As a result, the Company forecasts an operating loss of 680 million yen, which isa 349 million yen increase in loss compared to the previously announced forecast, and an ordinary lossof 549 million yen, which is a 330 million yen increase in loss compared to the previously announced
forecast, despite foreign exchange valuation gains on foreign currency denominated assets.
In addition, the forecasted net loss attributable to shareholders of the parent company was revised to
1,291 million yen, a 921 million yen increase in net loss compared to the previously announced forecast,due largely to an income tax adjustment due to a reversal of deferred tax assets in the amount of 642
million yen as described in item 2 below.
2. Reversal of deferred tax assets
The revised forecast reflects an income tax adjustment due to a reversal of deferred tax assets in theamount of 642 million yen, arising as a result of an assessment of the recoverability of deferred tax
assets in consideration of the current business environment and performance trends.
*Earnings forecasts, financial projections, and other forecasts or forward-looking statements containedin this disclosure have been prepared by the Company at its discretion and based on information
available to the Company as of the date of this disclosure. Actual results may vary materially from theinformation contained in this disclosure as a result of changes to business, economic, financial, or otherassumptions and conditions.
[Contact]
Investor Relations
Tel: +81(0)3 5472 1125

2